AAUM (Average Assets Under Management) of ₹23.63 Cr for Jul-Sep 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 80.7% | 81.2% | ▲ +0.5% |
| Healthcare Services | 19.3% | 18.9% | ▼ -0.4% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Pharmaceuticals & Biotechnology | 81.2% | 81.8% | ▲ +0.6% |
| Healthcare Services | 18.9% | 18.2% | ▼ -0.7% |
Comparing Sep 2026 → Oct 2026
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Laurus Labs Limited ₹2.14 Cr |
Pharmaceuticals & Biotechnology | 6.82% | 8.12% | +1.30% |
| 2 | Dr. Reddy's Laboratories Limited ₹1.89 Cr |
Pharmaceuticals & Biotechnology | 6.65% | 7.15% | +0.50% |
| 3 | Divi's Laboratories Limited ₹2.84 Cr |
Pharmaceuticals & Biotechnology | 10.44% | 10.78% | +0.34% |
| 4 | Zydus Lifesciences Limited ₹70.56 L |
Pharmaceuticals & Biotechnology | 2.55% | 2.68% | +0.13% |
| 5 | Apollo Hospitals Enterprise Limited ₹1.99 Cr |
Healthcare Services | 7.43% | 7.54% | +0.11% |
| 6 | Gland Pharma Limited ₹56.41 L |
Pharmaceuticals & Biotechnology | 2.04% | 2.14% | +0.10% |
| 7 | Cipla Limited ₹1.77 Cr |
Pharmaceuticals & Biotechnology | 6.70% | 6.73% | +0.03% |
| # | Stock | Sector | Sep 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited ₹4.30 Cr |
Pharmaceuticals & Biotechnology | 17.01% | 16.32% | -0.69% |
| 2 | Max Healthcare Institute Limited ₹1.46 Cr |
Healthcare Services | 6.12% | 5.55% | -0.57% |
| 3 | Torrent Pharmaceuticals Limited ₹1.55 Cr |
Pharmaceuticals & Biotechnology | 6.25% | 5.89% | -0.36% |
| 4 | Biocon Limited ₹56.06 L |
Pharmaceuticals & Biotechnology | 2.28% | 2.13% | -0.15% |
| 5 | Krishna Institute Of Medical Sciences Limited ₹42.82 L |
Healthcare Services | 1.76% | 1.62% | -0.14% |
| 6 | Lupin Limited ₹1.12 Cr |
Pharmaceuticals & Biotechnology | 4.36% | 4.23% | -0.13% |
| 7 | Glenmark Pharmaceuticals Limited ₹79.12 L |
Pharmaceuticals & Biotechnology | 3.11% | 3.00% | -0.11% |
| 8 | Abbott India Limited ₹30.51 L |
Pharmaceuticals & Biotechnology | 1.25% | 1.16% | -0.09% |
| 9 | Fortis Healthcare Limited ₹91.50 L |
Healthcare Services | 3.55% | 3.47% | -0.08% |
| 10 | Alkem Laboratories Limited ₹70.52 L |
Pharmaceuticals & Biotechnology | 2.75% | 2.67% | -0.08% |
20 stocks — Oct 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹4.30 Cr |
Pharmaceuticals & Biotechnology |
16.32%
|
|
| 2 |
₹2.84 Cr |
Pharmaceuticals & Biotechnology |
10.78%
|
|
| 3 |
₹2.14 Cr |
Pharmaceuticals & Biotechnology |
8.12%
|
|
| 4 |
₹1.99 Cr |
Healthcare Services |
7.54%
|
|
| 5 |
₹1.89 Cr |
Pharmaceuticals & Biotechnology |
7.15%
|
|
| 6 |
₹1.77 Cr |
Pharmaceuticals & Biotechnology |
6.73%
|
|
| 7 |
₹1.55 Cr |
Pharmaceuticals & Biotechnology |
5.89%
|
|
| 8 |
₹1.46 Cr |
Healthcare Services |
5.55%
|
|
| 9 |
₹1.12 Cr |
Pharmaceuticals & Biotechnology |
4.23%
|
|
| 10 |
₹1.06 Cr |
Pharmaceuticals & Biotechnology |
4.03%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.